Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 449,810 | 408,742 | 501,693 | 486,030 | 452,117 |
| Cost of Goods | 119,750 | 103,537 | 127,062 | 120,166 | 126,138 |
| Gross Profit | 330,060 | 305,205 | 374,631 | 365,864 | 325,979 |
| Operating Expenses | 396,690 | 358,961 | 363,021 | 340,944 | 377,632 |
| Operating Income | -65,880 | -53,219 | 11,672 | 25,086 | -51,515 |
| Interest Expense | 3,846 | 3,870 | 3,817 | 3,804 | 4,749 |
| Other Income | 3,152 | 10,929 | 6,301 | 1,946 | 9,404 |
| Pre-tax Income | -66,574 | -46,160 | 14,156 | 23,228 | -46,860 |
| Income Tax | -8,676 | -9,666 | 1,215 | 5,857 | -63,888 |
| Net Income Continuous | -57,898 | -36,494 | 12,941 | 17,371 | 17,028 |
| Net Income | $-57,898 | $-36,494 | $12,941 | $17,371 | $17,028 |
| EPS Basic Total Ops | -0.32 | -0.20 | 0.07 | 0.10 | 0.10 |
| EPS Basic Continuous Ops | -0.32 | -0.20 | 0.07 | 0.10 | 0.10 |
| EPS Diluted Total Ops | -0.31 | -0.20 | 0.07 | 0.09 | 0.21 |
| EPS Diluted Continuous Ops | -0.32 | -0.20 | 0.07 | 0.09 | 0.21 |
| EBITDA(a) | $-38,018 | $-24,979 | $40,108 | $53,742 | $-23,765 |